赞德利布治疗复发或难治性惰性非霍奇金淋巴瘤的II期研究:ME-401-K02研究
这项II期研究评估赞德利布治疗复发或难治性滤泡性淋巴瘤或边缘区淋巴瘤的疗效与安全性,61例患者接受60 mg每日连续给药两个28天周期后改为间歇给药。客观缓解率75.4%(95%CI 62.7%-85.5%),完全缓解率24.6%(95%CI 14.5%-37.3%),中位起效时间58天,55.7%发生至少1例次≥3级治疗中出现的不良事件。
要点
- 客观缓解率75.4%(95%CI 62.7%-85.5%),完全缓解率24.6%(95%CI 14.5%-37.3%)。
- 70.5%(43/61)的患者在第8周前达到首次缓解,中位起效时间58天。
- 55.7%发生至少1例次≥3级治疗中出现的不良事件,因不良事件停药率14.8%,无赞德利布相关死亡。
核心结论
- 赞德利布在复发或难治性惰性非霍奇金B细胞淋巴瘤日本患者中显示出有利的疗效和耐受性。
- 这种独特的给药方案可能在减轻其他PI3Kδ抑制剂所见安全性问题的同时维持疗效。
研究设计与样本
- II期研究,61例复发或难治性滤泡性淋巴瘤或边缘区淋巴瘤患者接受赞德利布口服60 mg每日连续给药两个28天周期,之后每个周期第1-7天间歇给药,直至疾病进展或不可接受的毒性。
主要发现
- 客观缓解率为75.4%(95%CI 62.7%-85.5%),完全缓解率为24.6%(95%CI 14.5%-37.3%)。
- 中位起效时间为58天;70.5%(43/61)的患者在第8周前达到首次缓解。
- 至少1例次≥3级治疗中出现的不良事件发生于55.7%的患者:转氨酶升高8.2%,皮肤反应3.3%,腹泻、小肠结肠炎和肺部感染各1.6%(定义为特别关注的不良事件)。
- 因任何治疗中出现的不良事件而停药的比例为14.8%。
- 未发生赞德利布相关死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Zandelisib, a selective, potent PI3Kδ inhibitor, demonstrated favourable outcomes in patients with relapsed or refractory follicular lymphoma in a global phase II study. This phase II study evaluated the efficacy and safety of zandelisib for relapsed or refractory follicular lymphoma or marginal zone lymphoma. Sixty-one patients received zandelisib orally at 60 mg daily continuously in the first two 28-day cycles, followed by intermittent dosing on Days 1-7 following each cycle until progressive disease or unacceptable toxicity. Objective and complete response rates were 75.4% (95% confidence interval [CI], 62.7%-85.5%) and 24.6% (95% CI, 14.5%-37.3%) respectively. Median time to response was 58 days; 70.5% (43/61) of patients achieved their first response by Week 8. At least one Grade ≥ 3 treatment-emergent adverse event (TEAE) occurred in 55.7% of patients: transaminase elevation (8.2%); cutaneous reactions (3.3%); and diarrhoea, enterocolitis and lung infection (1.6% each), defined as adverse events of special interest. The discontinuation rate due to any TEAE was 14.8%. No zandelisib-related death occurred. Zandelisib showed favourable efficacy and tolerability in Japanese patients with relapsed or refractory indolent non-Hodgkin B-cell lymphoma. This unique dosing schedule may maintain efficacy while mitigating the safety issues observed with other PI3Kδ inhibitors (ClinicalTrials.gov number, NCT04533581).
引用
- Munakata W, Kumode T, Goto H, et al. A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 study. Br J Haematol. 2025. PMID: 39778876. doi:10.1111/bjh.19994
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。